Skip to main content
Premium Trial:

Request an Annual Quote

Indivumed, Personalis Partner to Enhance Cancer Genomics Database

NEW YORK – Indivumed and Personalis said today that they have entered into a new personalized oncology collaboration in the field of personalized oncology, under which they will integrate Indivumed's multiomic cancer database, IndivuType, with genome and transcriptome-level data collected for thousands of samples using Personalis' advanced cancer genomics technology.

"Adding Personalis' technology to the IndivuType multiomics profile will enable relevant discoveries in our collaborations with pharma and biotech and further our mission to advance precision oncology," Indivumed CEO and Founder Hartmut Juhl said in a statement.

According to the firm, IndivuType provides high-quality banked samples that enable a range of molecular profiling; now including Personalis' comprehensive genomic approach. This data is then paired with clinical and outcome data to allow biomarker discovery and other correlative cancer research.

"Pairing Indivumed's leading position as a premier quality clinical cancer biobank with our extensive genomics experience will result in one of the most comprehensive multiomics cancer databases in the world," added Personalis CEO John West. "More importantly we feel these databases will provide the insights needed to drive precision medicine in oncology."

The Scan

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in in human genomic research, and more.

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people 65 and older or at increased risk.